韩国红金生衍生多糖的改善作用对抗生素相关的腹
Su Ji Min1, Hiyoung Kim2, Noriko Yambe1
1College of Korean Medicine, Gachon University, Seongnam-si 13120, Republic of Korea.
Polymers
|January 23, 2024
概括
韩国红人参多糖 (KRG-P) 有效地减轻小鼠的抗生素相关腹 (AAD). KRG-P恢复了肠道微生物组的平衡和短链脂肪酸水平,改善了肠道健康.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗生素相关腹 (AAD) 是抗生素治疗的常见副作用,通常与肠道失调有关.
- 在小鼠中因林氏素引起的腹作为研究ADD病原和潜在治疗干预措施的模型.
- 韩国红人参衍生多糖 (KRG-P) 正在研究其潜在的健康益处.
研究的目的:
- 在小鼠模型中评估KRG-P对林氏素诱导的AAD的治疗效果.
- 研究KRG-P对肠道微生物群,短链脂肪酸 (SCFA) 生产和肠道屏障蛋白的影响.
- 阐明KRG-P改善AAD的机制.
主要方法:
- 在使用lincomycin.cin的小鼠中诱导了与抗生素相关的腹.
- 小鼠接受了两种不同剂量的KRG-P (100 mg/kg和300 mg/kg).
- 分析了肠道屏障蛋白质,微生物菌群组成和内SCFA含量.
主要成果:
- 在AAD小鼠中,KRG-P的使用显著改善了腹症状.
- KRG-P治疗调节了肠道微生物群,减少了有害细菌 (蛋白质细菌) 和增加了有益细菌 (Firmicutes).
- 给予KRG-P导致白内障中SCFA水平 (酸,酸,黄油酸) 的增加.
结论:
- KRG-P对抗生素相关的腹具有显著的改善作用.
- KRG-P的治疗效益归因于恢复肠道微生物平衡和SCFA的产生.
- 通过改善肠道屏障功能和微生物群平衡,KRG-P显示出作为管理AAD的治疗剂的潜力.
相关概念视频
01:20Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
218
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
218
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
120
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
120
01:17Drugs for Treatment of Diarrhea-Predominant IBS
176
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
176
01:17Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
203
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
203
01:27Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
01:21Drugs for Treatment of Constipation-Predominant IBS
170
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
170